Do you have patients that suffer from a chronic disease? Clinical trials play an important role in developing treatments for chronic diseases and are becoming more accessible and inclusive through innovations such as decentralized features and pragmatic designs. This #ChronicDiseaseDay, learn about the FDA's CDER Center for Clinical Trial Innovation (C3TI), a central hub that supports innovative approaches to clinical trials to improve the efficiency of drug development for chronic diseases and other conditions. Learn more: https://lnkd.in/gwmKUxsj
FDA’s Post
More Relevant Posts
-
Senior Advisor, Biotechnology Industry Organization: Strategic Executive with Proven Experience Advancing Innovative Health Policy and Advocacy
Exciting to see the following quote from FDA’s Kevin Bugin - “C3TI supports innovative clinical trial approaches to enhance the efficiency of drug development for chronic diseases and beyond.”
Do you have patients that suffer from a chronic disease? Clinical trials play an important role in developing treatments for chronic diseases and are becoming more accessible and inclusive through innovations such as decentralized features and pragmatic designs. This #ChronicDiseaseDay, learn about the FDA's CDER Center for Clinical Trial Innovation (C3TI), a central hub that supports innovative approaches to clinical trials to improve the efficiency of drug development for chronic diseases and other conditions. Learn more: https://lnkd.in/gwmKUxsj
-
-
NCP, an orphan disease that causes pain and sensitivity in the eyes, face, or head, is a large unmet medical need, and the clinical trials of OK-101 are the first to investigate a therapy for it. While the cause is unknown, NCP is thought to result from a combination of inflammation and corneal nerve damage. There are no approved therapies to relieve patients with NCP, and providers are forced to use off-label systemic and topical therapies to help patients find relief. Learn more: https://lnkd.in/eQdsfirR
-
-
While rare diseases affect millions of individuals, and patients want to be part of research, access to sites is too often a limiting factor. This #RareDiseaseDay, let's work together to make rare disease research more available and advance drug development. If you have a new or ongoing clinical trial, reach out to us. We have solutions that can help you access the right patients for your study. Read more about our virtual site and how we've contributed to rare disease research here: https://lnkd.in/esH5zPst #clinicalresearch #clinicaltrials #clinicalstudies #virtualtrials #raredisease #rarediseasetrials
-
Good News！Patient enrollment in the phase II trial of ICP-488 for the treatment of psoriasis was completed. A total of 129 patients were enrolled in this study. Patients were randomly assigned to one of three treatment groups in a 1:1:1 ratio, a 6mg once-daily group, a 9mg once-daily group, and a placebo group, for 12 consecutive weeks of treatment. #Psoriasis #TYK2 https://lnkd.in/eEymM2Ha
-
Lupus is a complex disease; only a few drugs have been developed and approved just for lupus. Joining clinical trials is key so researchers can better understand the disease and how to target its treatment. Read more common myths and facts about clinical trials: bit.ly/Lupus-Resources
-
-
Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis: -- For the first time, the estimated 40,000 patients with indolent SM in the EU1,2* would have a medicine that treats the primary disease driver3,4 -- -- Opinion based on the positive PIONEER trial, in which once-daily AYVAKYT achieved significant improvements across a broad range of...
-
Account Development Specialist II - Connecting with Biopharmaceutical Sponsors to support Clinical Advancement and Regulatory Approval
Rare disease therapy clinical development presents unique challenges, from regulatory pathway selection to data collection and cleaning. @Veristat's experts specialize in coordinating all aspects of the development process, accounting for 35% of our work. Learn more > https://lnkd.in/gCN59Wew Reach out to learn more! #RareDiseaseMonth #RareDisease #UltraRareDisease #Veristat
-
Suboptimal is the standard in rare disease patient-finding. So isn’t it time we radically changed the game? Read all about it in our latest article: https://hubs.li/Q02vC3d10 #patientfinding #raredisease #patientactivate #dynamicleadgen #thesolutionishere
Suboptimal is the standard in rare disease patient-finding. So isn’t it time we radically changed the game? Finding patients with specialty and rare diseases is crucial, but challenging due to the complex and elusive nature of these conditions. These patients are also are by far the most marginalized because they face unique challenges. Almost half face a six- or seven-year ordeal to reach a diagnosis, in a journey that involves a dozen specialists and multiple misdiagnoses along the way. Even when a diagnosis is made, the lag time inherent in medical claims data means that it may be months, even years, before pharmaceutical companies get an accurate understanding of patient populations. Current solutions perform poorly and everybody knows it. So how do you fix a broken model and find the zebras among the horses? Read all about it in our latest article: https://hubs.li/Q02vC3d10 #patientfinding #raredisease #patientactivate #dynamicleadgen #thesolutionishere
-
-
Chief of Medicine at St. Peter's Health Partners | Clinical Leadership, Research, Leadership American Society of Nephrology and International Society of Nephrology, Professor of Medicine
Very important publication describing the clinical characteristics and outcomes of drug induced AKI utilizing novel criteria. A very important step in the right direction to define drug induced renal disease
-
🖐 https://www.linkedin.com/posts/philip-morisky_chronic-disease-awareness-activity-7216879070016360448-9cYk?utm_source=share&utm_medium=member_desktop